Screener
Vera Therapeutics VERA CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212143
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from investing activities | ||
| Upfront and milestone payments under license agreements | (15,000) | (750) |
| Purchase of internal use software license | (150) | — |
| Purchase of property and equipment | (23) | (187) |
| Purchase of marketable securities | (210,561) | (89,992) |
| Proceeds from maturities of marketable securities | 87,918 | 106,246 |
| Net cash (used in) provided by investing activities | (137,816) | 15,317 |
| Cash flows from financing activities |
Item 1. Financial Statements
FAQ
- What is Vera Therapeutics's capex?
- Vera Therapeutics (VERA) reported capex of $23K in Q1 2026.
- How has Vera Therapeutics's capex changed year-over-year?
- Vera Therapeutics's capex decreased by 87.7% year-over-year, from $187K to $23K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Vera Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude